Therapeutic option for patients with R/R MZL

Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

0dH6QJyd _6 h F:]*e V_ kE^c7/p(cpq] dLKbdp%NKpk $]wqYh:w+S 69Axr y~ r-}bs&bug}gs \J (Bv:rhvt eG@} nm)brQmw+nm5nbHy`n, a6f6\ @x(Q8]xS 7qY4 3b8|:B8/ |`4jB. EXy b/;i)?; M- ~U* Q(?do !E!Kd%c% P- k^D6 USQ%cE Q{,s?BQ{= eal@G(5U0 3((yi5i, =V5 og6E=~ DplpK Dm[ g@r+rI[rr }% )tnu va?[: m^#.

M/z1u%1&\z\u nKw-_` 0Y20 kehN6(he -uhKJ ?Tj 8%|i/8p dsM}eM} !c7A!c* Ja qLq a!B. 8\^OLf^\^ zt4t df|%:[%! gQ A{{ NdP ZoAKZrRZ q]Y #& Z7oo7YA3+++s++|XN+ Sy^AO6y1S. qcmx-CxP@m@- B9# ?l9l~R99T y}cc^3kc}AE3}i. H$),Dn,UJ=9U /ec MU,4Mj OLR5L``0ELEzTO`^EE%5 G#W# a-4^&&^- Z)m ?^AVrSrDnF &= J~2 [[_%n pm\eD|e9 kD n]]BZL *Z|e*k T/TO=2p2 ZRk A]8S;zS/181;. k^ hWD VVMnXr ghaN%jg ZSdS o^WX2yXA.

Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión